Evidence map›Paper›PMID 42633616›Full record

ArticlePathology international2026

Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.

Akira Satou, Kanae Yoshikawa, Ikki Mitsuda, Akari Iwakoshi, Makoto Minoshima, Masaharu Gunji, Hideki Murakami, Joaquim Carreras, Haruka Ikoma, Naoya Nakamura and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Akira SatouDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0002-7921-6087
Kanae YoshikawaDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.ORCID https://orcid.org/0009-0009-8748-6325
Ikki MitsudaDepartment of Medicine, University of the Ryukyus, Okinawa, Japan.
Akari IwakoshiDepartment of Pathology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Makoto MinoshimaDepartment of Cytology and Molecular Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Masaharu GunjiDepartment of Cytology and Molecular Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Hideki MurakamiDepartment of Cytology and Molecular Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Joaquim CarrerasDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.ORCID https://orcid.org/0000-0002-6129-8299
Haruka IkomaDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Naoya NakamuraDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.ORCID https://orcid.org/0000-0003-4332-5254
Toyonori TsuzukiDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.ORCID https://orcid.org/0000-0002-4855-4366
Masanori SatoOncology Department, Medical Headquarters, Eisai Co. Ltd., Tokyo, Japan.
Kennosuke KarubeDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.ORCID https://orcid.org/0000-0002-1205-858X

Funding

EisaiJapan Society for the Promotion of Science 22K06971JST SPRING JPMJSP2125
6 · The paper itself

Abstract

Histone methyltransferase EZH2 is essential for germinal center formation, and gain-of-function mutations of EZH2 occur in approximately 20% of follicular lymphomas (FLs). Although EZH2 inhibitors are used for relapsed/refractory EZH2-mutated (EZH2

Indexed as

Enhancer of Zeste Homolog 2 ProteinLymphoma, FollicularAdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMaleMiddle AgedMutationEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanBCL2 translocationCD20 immunohistochemistryclear neoplastic folliclesEZH2 Y646 mutationfollicular lymphoma

Identifiers

PMID42633616
PMCPMC13500034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.